Scancell: Response to Press Speculation
Scancell Holdings PLC (AIM: SCLP) has confirmed it is in advanced discussions over a proposed reverse merger with US-listed Neuphoria Therapeutics, a move that could secure the cancer immunotherapy developer a Nasdaq listing.
Responding to recent market speculation, Scancell said it is negotiating an all-share acquisition of Neuphoria, with the transaction intended to provide access to the US capital markets and increase the company’s visibility among specialist biotechnology investors.
Alongside the proposed merger, Scancell is also in discussions over a combination of equity and debt financing to fund the planned global Phase III registrational trial of its lead cancer immunotherapy candidate, iSCIB1+.
The company said the reverse merger and associated financing remain subject to final negotiations and definitive agreements. It cautioned that there is no certainty either transaction will proceed or that financing will be secured on acceptable terms.
If completed, the deal would represent a significant strategic milestone for Scancell, providing a potential Nasdaq listing while supporting the late-stage clinical development of its lead oncology programme.

